$KRRO

Dolan Oliver sold $37K of KRRO

Dolan Oliver (Senior Vice President, Finance) sold 3,383 shares of Korro Bio, Inc. (KRRO) at $10.83 on 2026-06-16.

Original reporting
SEC EDGAR · Dolan Oliver
Published Jun 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
low confidence
Mentioned
$KRRO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by the company’s SVP Finance, including trade size, price, and holdings after the transaction.

02

Market read

Traders may monitor for follow-on insider activity or corroborating company news, but this single Form 4 does not provide a direct fundamental catalyst.

03

What to watch

The filing does not state whether the sale was for taxes, diversification, or other non-informational reasons; absence of a 10b5-1 plan increases speculation but does not prove intent.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-17, covering sale dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Korro Bio, Inc.

Company-level read

Ticker impact

$KRRONeutralLow confidence
Context

Korro Bio Form 4 shows SVP Finance Dolan Oliver sold 3,383 shares at $10.83 on 2026-06-16, disclosing post-sale holdings.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or company-specific news.

Evidence & confidence

The filing is a routine insider transaction with no accompanying operational or guidance change. Lack of a 10b5-1 plan can increase interpretive noise, but the article provides no further context (e.g., tax, diversification, or planned sales).

Market effects

No sector-wide implications are disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is small relative to typical insider holdings and lacks stated rationale, it may reflect routine liquidity needs rather than negative fundamentals.

Key entities

  • Korro Bio, Inc.

    Subject of the Form 4 insider transaction disclosure (KRRO).

  • Dolan Oliver

    Senior Vice President, Finance who sold shares via open-market sale.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria